Why is Glenmark Pharma falling/rising?

As of 11-Aug, Glenmark Pharmaceuticals Ltd. is experiencing a price increase, with its current price at Rs 2,046.50, reflecting a rise of 28.1 points or 1.39%. Today's price summary indicates that the stock outperformed its sector by 0.48%, reaching an intraday high of Rs 2,063.2, which is a 2.22% increase. Despite a recent decline in delivery volume, which fell by 66.07% against the 5-day average, the stock remains liquid enough for trading. Over the past year, Glenmark has generated a substantial return of 39.12%, supported by a significant profit increase of 241.1%. The company also boasts a low Debt to EBITDA ratio of 1.00, high institutional holdings at 38.3%, and consistent returns over the last three years, all contributing positively to its recent performance.
In the broader market context, Glenmark's short-term performance has been relatively strong compared to the benchmark, as it has outperformed the Sensex, which has seen a decline of 0.51% over the past week while Glenmark's stock decreased by only 1.33%. This indicates that, despite some short-term volatility, Glenmark's overall performance remains robust, particularly in light of its strong fundamentals and positive quarterly results. The stock's ability to maintain a fair valuation and its significant returns over multiple periods further reinforce its resilience in the market.